Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the recipient of a large drop in short interest in November. As of November 30th, there was short interest totalling 6,800 shares, a drop of 40.4% from the November 15th total of 11,400 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average daily volume of 610,700 shares, the days-to-cover ratio is presently 0.0 days.
Bluejay Diagnostics Price Performance
Shares of Bluejay Diagnostics stock remained flat at $4.10 during mid-day trading on Thursday. 16,400 shares of the company’s stock traded hands, compared to its average volume of 176,480. Bluejay Diagnostics has a one year low of $3.03 and a one year high of $1,372.00. The stock has a fifty day moving average of $4.71 and a 200-day moving average of $40.15. The company has a market cap of $2.27 million, a PE ratio of 0.00 and a beta of 0.70.
Institutional Trading of Bluejay Diagnostics
A hedge fund recently raised its stake in Bluejay Diagnostics stock. Anson Funds Management LP increased its holdings in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) by 359.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 319,280 shares of the company’s stock after purchasing an additional 249,770 shares during the period. Anson Funds Management LP owned 1.93% of Bluejay Diagnostics worth $41,000 as of its most recent filing with the Securities and Exchange Commission. 18.47% of the stock is owned by institutional investors.
Bluejay Diagnostics Company Profile
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Read More
- Five stocks we like better than Bluejay Diagnostics
- P/E Ratio Calculation: How to Assess Stocks
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
- CD Calculator: Certificate of Deposit Calculator
- Intel Stock: A Value Play in the Quantum Computing Space
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.